Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

575 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
DSTYK Inhibition Sensitizes Non-Small Cell Lung Cancer To Taxane-Based Chemotherapy.
Echepare M, Picabea B, Arricibita A, Teijeira Á, Pasquier A, Zandueta C, Otegui N, Santamaría E, Fernández-Irigoyen J, Romero O, Sanchez-Cespedes M, Lecanda F, Hernández J, Felip E, Cruz-Bermúdez A, Provencio M, Gentili M, Facchinetti F, Roz L, Montuenga LM, Valencia K. Echepare M, et al. Among authors: felip e. J Thorac Oncol. 2024 Nov 11:S1556-0864(24)02438-9. doi: 10.1016/j.jtho.2024.11.003. Online ahead of print. J Thorac Oncol. 2024. PMID: 39536877
Development of a prognostic model to predict 90-day mortality in hospitalised cancer patients (PROMISE tool): a prospective observational study.
Mirallas O, Martin-Cullell B, Navarro V, Vega KS, Recuero-Borau J, Gómez-Puerto D, López-Valbuena D, Salva de Torres C, Andurell L, Pedrola A, Berché R, Palmas F, Ucha JM, Villacampa G, Rezqallah A, Sanz-Beltran J, Bach R, Bueno S, Viaplana C, Molina G, Hernando-Calvo A, Aguilar-Company J, Roca M, Muñoz-Couselo E, Martínez-Martí A, Alonso A, Eremiev S, Macarulla T, Oaknin A, Saura C, Élez E, Felip E, Peñuelas Á, Burgos R, Pardo PG, Garralda E, Tabernero J, Serradell S, Servitja S, Paez D, Dienstmann R, Carles J. Mirallas O, et al. Among authors: felip e. Lancet Reg Health Eur. 2024 Oct 9;46:101063. doi: 10.1016/j.lanepe.2024.101063. eCollection 2024 Nov. Lancet Reg Health Eur. 2024. PMID: 39529819 Free PMC article.
Plain language summary: tarlatamab for patients with previously treated small cell lung cancer.
Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, Juan-Vidal O, Handzhiev S, Izumi H, Lee JS, Dziadziuszko R, Wolf J, Blackhall F, Reck M, Alvarez JB, Hummel HD, Dingemans AC, Sands J, Akamatsu H, Owonikoko TK, Ramalingam SS, Borghaei H, Johnson ML, Huang S, Mukherjee S, Minocha M, Jiang T, Martinez P, Anderson ES, Paz-Ares L. Ahn MJ, et al. Among authors: felip e. Future Oncol. 2024 Nov 12:1-10. doi: 10.1080/14796694.2024.2402152. Online ahead of print. Future Oncol. 2024. PMID: 39530627
Deciphering HER2-low breast cancer (BC): insights from real-world data in early stage breast cancer.
Pous A, Bernat-Peguera A, López-Paradís A, Cirauqui B, Quiroga V, Teruel I, Felip E, Ferrando-Díez A, Bergamino M, Boronat L, Romeo M, Soler G, Mariño C, Rodríguez-Martínez P, Pons L, Ballana E, Martinez-Cardús A, Margelí M. Pous A, et al. Among authors: felip e. Ther Adv Med Oncol. 2024 Oct 23;16:17588359241290720. doi: 10.1177/17588359241290720. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39449733 Free PMC article.
Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC.
Santoro A, Pilar G, Tan DSW, Zugazagoitia J, Shepherd FA, Bearz A, Barlesi F, Kim TM, Overbeck TR, Felip E, Cai C, Simantini E, McCulloch T, Schaefer ES. Santoro A, et al. Among authors: felip e. BMC Cancer. 2024 Oct 24;24(1):1307. doi: 10.1186/s12885-024-12841-2. BMC Cancer. 2024. PMID: 39448966 Free PMC article. Clinical Trial.
Lung Cancer Research and Treatment: Global Perspectives and Strategic Calls to Action.
Meyer ML, Peters S, Mok TS, Lam S, Yang PC, Aggarwal C, Brahmer J, Dziadziuszko R, Felip E, Ferris A, Forde PM, Gray J, Gros L, Halmos B, Herbst R, Jänne PA, Johnson BE, Kelly K, Leighl NB, Liu S, Lowy I, Marron TU, Paz-Ares L, Rizvi N, Rudin CM, Shum E, Stahel R, Trunova N, Ujhazy P, Bunn PA Jr, Hirsch FR. Meyer ML, et al. Among authors: felip e. Ann Oncol. 2024 Oct 14:S0923-7534(24)04055-9. doi: 10.1016/j.annonc.2024.10.006. Online ahead of print. Ann Oncol. 2024. PMID: 39413875 Review.
A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer.
Planchard D, Wolf J, Solomon B, Sebastian M, Wermke M, Heist RS, Sun JM, Min Kim T, Reguart N, Sanmamed MF, Felip E, Garrido P, Santoro A, Bootle D, Couillebault XM, Gaur A, Mueller C, Poggio T, Yang J, Moschetta M, Dooms C. Planchard D, et al. Among authors: felip e. Lung Cancer. 2024 Nov;197:107964. doi: 10.1016/j.lungcan.2024.107964. Epub 2024 Sep 26. Lung Cancer. 2024. PMID: 39383771 Clinical Trial.
Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer.
Solomon BJ, Liu G, Felip E, K Mok TS, Soo RA, Mazieres J, Shaw AT, Marinis F, Goto Y, Wu YL, Kim DW, Martini JF, Messina R, Paolini J, Polli A, Thomaidou D, Toffalorio F, Bauer TM. Solomon BJ, et al. Among authors: felip e. Future Oncol. 2024 Oct 3:1-11. doi: 10.1080/14796694.2024.2406117. Online ahead of print. Future Oncol. 2024. PMID: 39360949
Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study.
Neal JW, Santoro A, Gonzalez-Cao M, Lim FL, Fang B, Gentzler RD, Goldschmidt J, Khrizman P, Proto C, Patel S, Puri S, Liu SV, Massarelli E, Williamson D, Schwickart M, Scheffold C, Andrianova S, Felip E. Neal JW, et al. Among authors: felip e. JTO Clin Res Rep. 2024 Mar 20;5(10):100666. doi: 10.1016/j.jtocrr.2024.100666. eCollection 2024 Oct. JTO Clin Res Rep. 2024. PMID: 39318387 Free PMC article.
575 results